High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.062
-58.67%
--
--
-0.092
-28.85%
--
--
-0.100
-16.67%
Estimates Revision
The market is revising No Change the revenue expectations for Reviva Pharmaceuticals Holdings, Inc. (RVPH) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 34.67%.
EPS Estimates for FY2025
Revise Downward
-6.21%
In Past 3 Month
Stock Price
Go Up
+34.67%
In Past 3 Month
7 Analyst Rating
Wall Street analysts forecast RVPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVPH is 5.14 USD with a low forecast of 2.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.591
Low
2.00
Averages
5.14
High
16.00
Current: 0.591
Low
2.00
Averages
5.14
High
16.00
H.C. Wainwright
Buy
downgrade
$11 -> $4
2025-10-27
Reason
H.C. Wainwright
Price Target
$11 -> $4
2025-10-27
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Reviva Pharmaceuticals to $4 from $11 and keeps a Buy rating on the shares. The firm cites the company's two "highly dilutive" financing transactions in June and September for the target cut.
Chardan
NULL -> Buy
initiated
$2
2025-09-29
Reason
Chardan
Price Target
$2
2025-09-29
initiated
NULL -> Buy
Reason
Chardan initiated coverage of Reviva Pharmaceuticals with a Buy rating and $2 price target. The firm cites the potential of the company's lead asset brilaroxazine as a next-generation antipsychotic product for the Buy rating. Reviva's brilaroxazine is a "real product" that could get approval in schizophrenia and find a niche in a large but highly genericized market, the analyst tells investors in a research note.
D. Boral Capital
Jason Kolbert
Buy
downgrade
$3 -> $2
2025-09-19
Reason
D. Boral Capital
Jason Kolbert
Price Target
$3 -> $2
2025-09-19
downgrade
Buy
Reason
D. Boral Capital analyst Jason Kolbert lowered the firm's price target on Reviva Pharmaceuticals to $2 from $3 and keeps a Buy rating on the shares. The company has executed on back-to-back capital raises that provide $19M in gross proceeds and reinforce its near-term financial runway, the analyst tells investors in a research note. The firm says that while Reviva's balance sheet is strengthened, the company's dilution overhang has expanded.
Benchmark
Speculative Buy
downgrade
$14 -> $7
2025-09-15
Reason
Benchmark
Price Target
$14 -> $7
2025-09-15
downgrade
Speculative Buy
Reason
Benchmark lowered the firm's price target on Reviva Pharmaceuticals to $7 from $14 and keeps a Speculative Buy rating on the shares ahead of the completion of a meeting with the FDA scheduled for Q4 to discuss the future NDA submission for brilaroxazine, which the firm calls "the next major catalyst for the shares." The data so far have demonstrated Brilaroxazine has better efficacy, fewer side-effects, higher patient compliance, and easy dosing compared to existing alternatives for the treatment of schizophrenia, says the analyst, who adds that the company will likely need additional capital in order to move its clinical programs forward.
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$7 -> $3
2025-08-18
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$7 -> $3
2025-08-18
downgrade
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Reviva Pharmaceuticals to $3 from $7 and keeps a Buy rating on the shares after meeting with its management team regarding its Q2 performance and its commercial outlook. The company's upcoming FDA Type C meeting presents an intriguing scenario to buy the stock at the current price given the opportunity to bypass a second Phase 3 study, the analyst tells investors in a research note. Roth adds however that its price target cut reflects equity dilution and its discount cash-flow model updates.
Maxim
Jason McCarthy
Buy
downgrade
$5 -> $2
2025-08-18
Reason
Maxim
Jason McCarthy
Price Target
$5 -> $2
2025-08-18
downgrade
Buy
Reason
Maxim analyst Jason McCarthy lowered the firm's price target on Reviva Pharmaceuticals to $2 from $5 and keeps a Buy rating on the shares. The firm is positive on the company's plans to meet with the FDA or the brilaroxazine program in Q4 to discuss the potential for an NDA submission, though its price target cut reflects its recent equity dilution, the analyst tells investors in a research note.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Reviva Pharmaceuticals Holdings Inc (RVPH.O) is -1.61, compared to its 5-year average forward P/E of -3.49. For a more detailed relative valuation and DCF analysis to assess Reviva Pharmaceuticals Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.49
Current PE
-1.61
Overvalued PE
-0.25
Undervalued PE
-6.72
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
RVPH News & Events
Events Timeline
(ET)
2025-12-02
08:50:00
Sealsq Corp (LAES) Borrow Rate Hits 81.71%, Leading Liquid Options
2025-11-24 (ET)
2025-11-24
08:45:01
Significant Borrowing Rate Hikes Among Liquid Assets
2025-11-13 (ET)
2025-11-13
16:22:14
Reviva Pharmaceuticals Reports Q3 Earnings Per Share of 6 Cents, Below Consensus Estimate of 10 Cents
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/fc8a7412c0d101c762e6926409fcec60e040b02534621fedee72010f4f18e5dc.jpg)
Preview
2.0
12-01NASDAQ.COMBiotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/default_image/benzinga.png)
Preview
6.0
11-19BenzingaD. Boral Capital Reiterates Buy Rating on Reviva Pharmaceuticals with $2 Price Target Intact
Preview
6.0
10-29BenzingaD. Boral Capital Reiterates Buy Rating for Reviva Pharmaceuticals, Upholds $2 Price Target
Sign Up For More News
People Also Watch
FAQ
What is Reviva Pharmaceuticals Holdings Inc (RVPH) stock price today?
What is Reviva Pharmaceuticals Holdings Inc (RVPH)'s business?
What is the price predicton of RVPH Stock?
What is Reviva Pharmaceuticals Holdings Inc (RVPH)'s revenue for the last quarter?
What is Reviva Pharmaceuticals Holdings Inc (RVPH)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Reviva Pharmaceuticals Holdings Inc (RVPH)'s fundamentals?
How many employees does Reviva Pharmaceuticals Holdings Inc (RVPH). have?